Quick Answer
Serina Therapeutics, Inc. reported Cash and Equivalents of $3.06 million for fiscal year 2025.
Serina Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.06M | -16.8% |
| 2024 | $3.67M | -51.8% |
| 2023 | $7.62M | +1081.2% |
| 2022 | $645.0K | +10.4% |
| 2021 | $584.0K | +10.8% |
| 2020 | $527.0K | -77.6% |
| 2019 | $2.35M | -64.9% |
| 2018 | $6.71M | -9.1% |
| 2017 | $7.38M | +2747.5% |
| 2016 | $259.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.62M | +170.6% | +42.7% |
| June 30, 2025 | $6.04M | -0.4% | +41.6% |
| March 31, 2025 | $4.27M | -51.0% | +16.2% |
| December 31, 2024 | $3.67M | -51.8% | +15.3% |
| September 30, 2024 | $3.19M | +702.3% | -47.5% |
| June 30, 2024 | $6.06M | +2223.4% | -30.3% |
| March 31, 2024 | $8.71M | +3009.3% | +14.3% |
| December 31, 2023 | $7.62M | +1081.2% | +1819.1% |
- Serina Therapeutics, Inc. showed a decrease of -16.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Serina Therapeutics, Inc.’s cash and equivalents has grown by 1079.9% (from $259.0 thousand to $3.06 million).
- The most recent figure is from Serina Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: